Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plamotamab in Rheumatoid Arthritis
NCT07230353Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Plamotamab in rheumatoid arthritis (RA), sponsored by Xencor. Primary endpoint: Safety and Tolerability at 52 weeks. Started Oct 2025; status: recruiting.
02
Drugs
Plamotamab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07230353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230353.